XERS - ゼリス・ファ―マシュ―ティカルズ （Xeris Pharmaceuticals Inc.） ゼリス・ファ―マシュ―ティカルズXERSのチャート
XERSの企業情報
| symbol | XERS |
|---|---|
| 会社名 | Xeris Pharmaceuticals Inc （ゼリス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing injectable and infusible drug formulations. It uses its non-aqueous formulation technology platforms XeriSol and XeriJect to develop and commercialize its products. Its formulation technologies allow for the subcutaneous (SC) and intramuscular (IM) delivery of formulations of peptides proteins antibodies and small molecules using commercially-available syringes auto-injectors multi-dose pens and infusion pumps. The Company is developing its lead product candidate the Glucagon Rescue Pen for the treatment of severe hypoglycemia in people with diabetes. It is also developing treatments for post-bariatric hypoglycemia congenital hyperinsulinism hypoglycemia-associated autonomic failure and exercise-induced hypoglycemia. Its Glucagon Rescue Pen offers a stable glucagon that is designed to be administered subcutaneously in a simple two-step process. ゼリス・ファ―マシュ―ティカルズは米国の特殊医薬品企業。疾患に対して、直ちに注射可能または注入可能な医薬品の開発・商品化に従事する。患者の皮下および筋肉内送達ができるペン型注射や注入ポンプに使用されるペプチド、タンパク質、抗体および小分子の製剤を開発する。同社リ―ド製品候補は糖尿病患者の低血糖を治療する。本社所在地はイリノイ州シカゴ。 Xeris Pharmaceuticals Inc. is a specialty pharmaceutical company delivering innovative solutions to simplify the experience of administering important therapies that people rely on every day around the world. |
| 本社所在地 | 180 North LaSalle Street Suite 1810 Chicago IL 60601 USA |
| 代表者氏名 | Paul R. Edick ポールRエディック |
| 代表者役職名 | President Chief Executive Officer Director 社長兼最高経営責任者（CEO） |
| 電話番号 | +1 512-498-2670 |
| 設立年月日 | 2005年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.xerispharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/xers |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -40.62100 |
| 終値（lastsale） | 19.82 |
| 時価総額（marketcap） | 412599143.66 |
| 時価総額 | 時価総額（百万ドル） 385.32850 |
| 売上高 | 売上高（百万ドル） 1.71900 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 268.96750 |
| 当期純利益 | 当期純利益（百万ドル） -41.56700 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Xeris Pharmaceuticals Inc revenues increased 18% to $1.1M. Net loss increased from $9.9M to $24.9M. Revenues reflect Grant income increase of 14% to $1M Service revenue increase from $16K to $53K. Higher net loss reflects Research and develop increase from $7.8M to $17.1M (expense) General and administrative - increase from $2.7M to $7.4M (expense) Interest expense increase from $1K to $753K (expense). |
XERSのテクニカル分析
XERSのニュース
Xeris stock trades higher on US patent covering XeriSol formulations 2023/04/18 11:42:03 Seeking Alpha
Xeris Biopharma (XERS) said that the U.S. Patent and Trademark Office issued a patent covering its XeriSol formulations. Read more here
Xeris Pharmaceuticals Issued US Patent Covering XeriSol Formulations 2023/04/18 11:02:04 Investing.com
https://www.investing.com/news/assorted/xeris-pharmaceuticals-issued-us-patent-covering-xerisol-formulations-432SI-3057885
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol Formulations 2023/04/18 11:00:00 Wallstreet:Online
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC
Xeris Biopharma Announces Issuance of U.S. Patent Covering XeriSol™ Formulations 2023/04/18 11:00:00 Business Wire
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the U.S. Patent and Trademark Office has issued US Patent Number 11,590,205, entitled ‘METHODS FOR PRODUCING STABLE THERAPEUTIC GLUCAGON FORMULATIONS IN APROTIC POLAR SOLVENTS.’ The claims in this newly issued patent cover certain pharmace
Xeris Biopharma Holdings Inc. At $1.89: Buy, Sell Or Hold? 2023/04/06 11:30:00 Marketing Sentinel
Xeris Biopharma Holdings Inc. (NASDAQ:XERS)’s traded shares stood at 1.64 million during the last session, with the company’s beta value hitting 1.30. At the close of trading, the stock’s price was $1.89, to imply a decrease of -2.58% or -$0.05 in intraday trading. The XERS share’s 52-week high remains $2.72, putting it -43.92% down since … Xeris Biopharma Holdings Inc. At $1.89: Buy, Sell Or Hold? Read More »
Xeris Biopharma Holdings Inc. At $1.89: Buy, Sell Or Hold? 2023/04/06 11:30:00 Marketing Sentinel
Xeris Biopharma Holdings Inc. (NASDAQ:XERS)’s traded shares stood at 1.64 million during the last session, with the company’s beta value hitting 1.30. At the close of trading, the stock’s price was $1.89, to imply a decrease of -2.58% or -$0.05 in intraday trading. The XERS share’s 52-week high remains $2.72, putting it -43.92% down since … Xeris Biopharma Holdings Inc. At $1.89: Buy, Sell Or Hold? Read More »
Regeneron in research agreement with Xeris Biopharma 2023/03/30 11:17:56 Seeking Alpha
Xeris Biopharma (XERS) has inked an agreement with Regeneron (REGN) to use its drug-formulation platform, XeriJect, to develop monoclonal antibodies. Read more here.
Xeris Biopharma Announces Research Evaluation Collaboration and Option Agreement With Regeneron for XeriJect™ 2023/03/30 11:00:00 Business Wire
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and comm
Xeris Biopharma: Picks And Shovels Play Has Long-Term Growth Potential 2023/03/28 10:24:51 Seeking Alpha
Xeris Biopharma''s shares have lost over half their value during the past year. Click here to see why XERS stock is a Buy.
Xeris stock falls ~10% despite revenue growth, narrowed loss in Q4 2023/03/08 16:22:49 Seeking Alpha
Xeris Biopharma (XERS) stock fell ~10% on Wednesday despite Q4 results beat estimates.Net loss narrowed to -$12.93M, compared to -$50.79M in Q4 2021.Total revenue grew +54.6% to $33.14
Xeris Biopharma Announces Plans for a Phase II Dose-Finding Study for Its Investigational Subcutaneous (SC) Levothyroxine (XP-8121) as Replacement Therapy for Hypothyroidism 2022/12/15 12:00:00 Wallstreet:Online
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that, based on feedback from a Type C meeting with the Food and Drug Administration (FDA), Xeris will proceed with a Phase II study in patients for its novel formulation
Analyst Updating Price Targets And Ratings For Xeris Biopharma Holdings Inc. (XERS) 2022/11/25 14:30:00 Stocks Register
Xeris Biopharma Holdings Inc. (NASDAQ:XERS) concluded the trading at $1.32 on Wednesday, November 23 with a rise of 3.94% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $1.27 with its price kept floating in the range of $1.28 and $1.43 on … Analyst Updating Price Targets And Ratings For Xeris Biopharma Holdings Inc. (XERS) Read More »
Xeris, Horizon team up to develop ready-to-use form of thyroid eye disease drug 2022/11/23 11:49:28 Seeking Alpha
Xeris Biopharma (XERS) said it entered a research collaboration and option agreement with Horizon Therapeutics (HZNP) for XeriJect formulation of teprotumumab,Teprotumumab-trbw is sold…
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect™ Formulation of Teprotumumab | MarketScreener 2022/11/23 11:02:01 MarketScreener
Xeris to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab … | November 23, 2022
Xeris Biopharma Announces Research Collaboration and Option Agreement With Horizon Therapeutics plc for XeriJect Formulation of Teprotumumab 2022/11/23 11:00:00 Wallstreet:Online
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into a research collaboration and option agreement with Horizon Therapeutics plc (Nasdaq: HZNP). Under the terms of the agreement, Xeris will use its